To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
408
Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
Placebo, oral, 2 capsules twice daily
The changes of pain scores after treatment in HSK16149 group and placebo group were compared with baseline
Changes in mean pain intensity (ADPS) at week 12 between HSK16149 and placebo were compared from baseline;The pain NRS score divides a straight line into 10 segments, with 0 to 10 indicating pain (a total of 11 points), 0 indicating no pain, and 10 indicating the most intense pain. The pain NRS scores of the past 7 days were collected and the average value was used as the ADPS score.
Time frame: week12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.